|
US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
|
US6277870B1
(en)
*
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
|
WO2002016356A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
AU2001282873A1
(en)
|
2000-08-18 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
WO2002016358A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
JP2004506734A
(ja)
*
|
2000-08-21 |
2004-03-04 |
ファルマシア・アンド・アップジョン・カンパニー |
疾患治療用のキヌクリド置換ヘテロアリール部分
|
|
WO2002017358A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
|
US6599916B2
(en)
|
2000-08-21 |
2003-07-29 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
US6562816B2
(en)
|
2001-08-24 |
2003-05-13 |
Pharmacia & Upjohn Company |
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
BR0212123A
(pt)
*
|
2001-08-24 |
2004-07-20 |
Upjohn Co |
7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
|
|
EP1425286B1
(en)
*
|
2001-09-12 |
2007-02-28 |
Pharmacia & Upjohn Company LLC |
Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
|
|
EA007429B1
(ru)
*
|
2001-10-02 |
2006-10-27 |
Фармация Энд Апджон Компани |
Азабициклические замещённые конденсированные гетероарильные соединения
|
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
|
CA2466375A1
(en)
|
2001-11-08 |
2003-05-15 |
Pharmacia & Upjohn Company |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
MXPA04004373A
(es)
*
|
2001-11-09 |
2004-08-11 |
Upjohn Co |
Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
|
|
CA2470567A1
(en)
|
2001-12-14 |
2003-06-26 |
Targacept, Inc. |
Methods and compositions for treatment of central nervous system disorders
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852716B2
(en)
|
2002-02-15 |
2005-02-08 |
Pfizer Inc |
Substituted-aryl compounds for treatment of disease
|
|
MXPA04008152A
(es)
*
|
2002-02-19 |
2005-09-08 |
Upjohn Co |
Compuestos azabiciclicos para el tratamiento de enfermedades.
|
|
CA2476681A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Bruce N. Rogers |
Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
|
|
MXPA04007083A
(es)
*
|
2002-02-20 |
2004-10-29 |
Upjohn Co |
Compuestos azabiciclicos para el tratamiento de enfermedades.
|
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
|
US7176198B2
(en)
|
2002-08-01 |
2007-02-13 |
Pfizer Inc. |
1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
|
|
JP2006501246A
(ja)
|
2002-08-30 |
2006-01-12 |
メモリー・ファーマシューティカルズ・コーポレイション |
神経変性疾患の治療において有用なアナバセイン誘導体
|
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
|
AU2003276919B2
(en)
|
2002-09-25 |
2013-05-16 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
|
|
BR0315056A
(pt)
*
|
2002-11-01 |
2005-08-16 |
Pharmacia & Upjohn Co Llc |
Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
|
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
|
CN1735414A
(zh)
|
2002-12-06 |
2006-02-15 |
北岸长岛犹太人研究学院 |
用α7受体结合类胆碱激动剂抑制炎症
|
|
MXPA05010496A
(es)
*
|
2003-03-28 |
2005-11-16 |
Pharmacia & Upjohn Co Llc |
Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
|
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
|
DE10334724A1
(de)
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
|
SI1678172T1
(sl)
|
2003-10-15 |
2010-04-30 |
Targacept Inc |
AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
|
|
FR2861076B1
(fr)
*
|
2003-10-17 |
2006-01-06 |
Sanofi Synthelabo |
Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
|
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
|
WO2005063767A2
(en)
|
2003-12-22 |
2005-07-14 |
Memory Pharmaceuticals Corporation |
Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
|
|
FR2865208B1
(fr)
*
|
2004-01-16 |
2009-01-16 |
Sanofi Synthelabo |
Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
|
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
|
US20050234095A1
(en)
|
2004-03-25 |
2005-10-20 |
Wenge Xie |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
|
|
JP2007534692A
(ja)
|
2004-04-22 |
2007-11-29 |
メモリー・ファーマシューティカルズ・コーポレイション |
インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
|
|
US7632831B2
(en)
|
2004-05-07 |
2009-12-15 |
Memory Pharmaceuticals Corporation |
1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
|
RU2418797C2
(ru)
|
2004-12-22 |
2011-05-20 |
Мемори Фармасьютиклз Корпорейшн |
Лиганды никотинового рецептора альфа-7, их получение и применение
|
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
|
EP2298410B1
(en)
|
2004-12-27 |
2013-10-09 |
The Feinstein Institute for Medical Research |
Treating inflammatory disorders by electrical vagus nerve stimulation
|
|
DE602006017235D1
(de)
|
2005-08-22 |
2010-11-11 |
Targacept Inc |
Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
|
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
|
TWI454262B
(zh)
*
|
2006-11-02 |
2014-10-01 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
|
TW200901974A
(en)
|
2007-01-16 |
2009-01-16 |
Wyeth Corp |
Compounds, compositions, and methods of making and using them
|
|
CA2678193A1
(en)
|
2007-02-09 |
2008-08-14 |
Astellas Pharma Inc. |
Aza-bridged-ring compound
|
|
WO2009013535A1
(en)
*
|
2007-07-23 |
2009-01-29 |
Astrazeneca Ab |
2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
|
CN104193741B
(zh)
|
2007-10-01 |
2016-08-24 |
阿尔法梅根有限责任公司 |
作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
|
|
RU2481123C2
(ru)
|
2008-02-13 |
2013-05-10 |
Таргасепт, Инк. |
Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств
|
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
|
TWI488854B
(zh)
|
2008-06-20 |
2015-06-21 |
Astrazeneca Ab |
二苯并噻氮呯衍生物及其用途
|
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
WO2010087762A1
(en)
*
|
2009-01-28 |
2010-08-05 |
Astrazeneca Ab |
2-aza-bicyclo[2.2.1]heptane compounds and uses thereof
|
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
|
CN102573986B
(zh)
|
2009-06-09 |
2016-01-20 |
赛博恩特医疗器械公司 |
用于无导线刺激器的具有袋部的神经封套
|
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
|
US11051744B2
(en)
|
2009-11-17 |
2021-07-06 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
|
WO2011079309A2
(en)
|
2009-12-23 |
2011-06-30 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
|
JP5749797B2
(ja)
|
2010-05-17 |
2015-07-15 |
フォルム ファーマシューティカルズ、インコーポレイテッド |
（ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形
|
|
DK2605655T3
(en)
|
2010-08-19 |
2019-02-04 |
Buck Institute For Age Res |
METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
|
|
EP2707094B1
(en)
|
2011-05-09 |
2016-02-03 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US12172017B2
(en)
|
2011-05-09 |
2024-12-24 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
|
CA2872005A1
(en)
|
2012-05-08 |
2013-11-14 |
Forum Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
|
MA37975B2
(fr)
*
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
JP6478923B2
(ja)
|
2013-02-07 |
2019-03-06 |
ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
|
|
SG11201506415XA
(en)
*
|
2013-03-15 |
2015-09-29 |
Genzyme Corp |
Method of preparing glucosylceramide synthase inhibitors
|
|
EA029430B1
(ru)
|
2013-06-21 |
2018-03-30 |
Такеда Фармасьютикл Компани Лимитед |
Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
|
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
|
US9434724B2
(en)
|
2014-07-11 |
2016-09-06 |
Alpharmagen, Llc |
Quinuclidines for modulating alpha 7 activity
|
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
|
WO2016126807A1
(en)
|
2015-02-03 |
2016-08-11 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
|
EP3405255A4
(en)
|
2016-01-20 |
2019-10-16 |
Setpoint Medical Corporation |
IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS
|
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
|
EP3405107B1
(en)
|
2016-01-20 |
2023-04-12 |
Setpoint Medical Corporation |
Control of vagal stimulation
|
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
|
CN113939334A
(zh)
|
2019-04-12 |
2022-01-14 |
赛博恩特医疗器械公司 |
迷走神经刺激来处理神经退行性障碍
|
|
AU2020384066B2
(en)
*
|
2019-11-15 |
2025-10-30 |
Green Cross Corporation |
Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
|
|
CN114746422B
(zh)
*
|
2019-11-15 |
2024-03-12 |
柳韩洋行 |
具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物
|
|
US12083115B2
(en)
|
2020-02-03 |
2024-09-10 |
Genzyme Corporation |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
|
KR20230012585A
(ko)
|
2020-05-21 |
2023-01-26 |
더 파인스타인 인스티튜츠 포 메디칼 리서치 |
미주 신경 자극을 위한 시스템들 및 방법들
|
|
BR112023000798A2
(pt)
|
2020-07-24 |
2023-02-07 |
Genzyme Corp |
Composições farmacêuticas compreendendo venglustat
|
|
BR112023022015A2
(pt)
*
|
2021-05-11 |
2023-12-26 |
Green Cross Corp |
Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas
|
|
US12444497B2
(en)
|
2021-05-17 |
2025-10-14 |
Setpoint Medical Corporation |
Neurostimulation parameter authentication and expiration system for neurostimulation
|
|
IL319915A
(en)
*
|
2022-10-24 |
2025-05-01 |
Yuhan Corp |
Improved processes for the preparation of dimethyl-3,2-dihydro-1H-indene derivatives
|
|
KR20240057364A
(ko)
*
|
2022-10-24 |
2024-05-02 |
주식회사유한양행 |
다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법
|
|
KR20250117295A
(ko)
*
|
2024-01-26 |
2025-08-04 |
주식회사유한양행 |
고셔병의 예방 또는 치료용 약제학적 조성물
|